Literature DB >> 16325968

Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.

Alice Panchaud1, Alain Sauty, Yann Kernen, Laurent A Decosterd, Thierry Buclin, Olivier Boulat, Christine Hug, Marianne Pilet, Michel Roulet.   

Abstract

BACKGROUND AND AIMS: Various anti-inflammatory therapies, including dietary omega-3 polyunsaturated fatty acids (PUFA) supplementation, have been investigated in cystic fibrosis (CF) patients. To further explore this nutritional approach, biological effects of an omega-3 PUFA oral liquid supplementation were measured in 17 CF patients in a double-blind, randomized, crossover without a washout period and placebo-controlled study.
METHODS: CF patients (age: 18+/-9 year; weight: 43+/-13 kg) received a liquid dietary supplementation either enriched or not in omega-3 PUFA (390-1170 mg/day according to patient weight) during two 6-month periods.
RESULTS: Increase in eicosapentaenoic acid was observed in neutrophil membrane following omega-3 PUFA dietary supplementation (from 0.7+/-0.6 to 1.6+/-0.6 micromol%, P<0.01). The leukotriene B(4) (LTB(4))/leukotriene B(5) (LTB(5)) ratio was decreased (from 72+/-27 to 24+/-7, P<0.001) in CF patients taking omega-3 PUFA supplements. In contrast, omega-3 PUFA supplementation affected neither internalization of IL-8 receptors following IL-8 exposure, nor IL-8-induced neutrophil chemotaxis.
CONCLUSION: Our results show that omega-3 PUFA are incorporated in neutrophil membranes. The subsequent decrease in LTB(4)/LTB(5) ratio suggests that, in such conditions, neutrophils may produce less pro-inflammatory mediators from the acid arachidonic pathway. These data indicate that omega-3 PUFA intake may have anti-inflammatory effect that still need to be assessed by long-term studies following large groups of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325968     DOI: 10.1016/j.clnu.2005.10.011

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  13 in total

1.  Omega-3 fatty acid supplementation for cystic fibrosis.

Authors:  Helen Watson; Caroline Stackhouse
Journal:  Cochrane Database Syst Rev       Date:  2020-04-10

2.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Authors:  Sarah W Njoroge; Michael Laposata; Waddah Katrangi; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

3.  Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; Paul R Gallagher; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-11       Impact factor: 2.839

4.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Sherie Smith; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2020-07-16

Review 5.  Omega-3 fatty acids for cystic fibrosis.

Authors:  Colleen Oliver; Helen Watson
Journal:  Cochrane Database Syst Rev       Date:  2016-01-05

Review 6.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

7.  Neutrophil generation of inflammatory precursors is not modulated by docosahexaenoic acid.

Authors:  Serena Quattrucci; Mariarosaria Napolitano; Sara Benedetti Valentini; Alessandro Giuliani; Elena Bravo
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

Review 8.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 9.  The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.

Authors:  Jillian Poles; Elisa Karhu; Megan McGill; H Reginald McDaniel; John E Lewis
Journal:  J Clin Transl Res       Date:  2021-05-27

10.  Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.

Authors:  Wojciech Janczyk; Piotr Socha; Dariusz Lebensztejn; Aldona Wierzbicka; Artur Mazur; Joanna Neuhoff-Murawska; Pawel Matusik
Journal:  BMC Pediatr       Date:  2013-05-23       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.